Can-Fite BioPharma (NYSE:CANF) Earns “Buy” Rating from HC Wainwright

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $18.00 target price on the stock.

CANF has been the subject of several other research reports. EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. StockNews.com lowered shares of Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $2.12 on Tuesday. Can-Fite BioPharma has a twelve month low of $1.83 and a twelve month high of $4.69. The company has a 50-day moving average of $2.27 and a 200-day moving average of $2.52. The firm has a market cap of $7.50 million, a price-to-earnings ratio of -1.18 and a beta of 1.39.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.